所有发表论文： PubMed Google Scholar 交医官网
代表性论文：
2023. Sci Adv. Therapeutic targeting of CPSF3-dependent transcriptional termination in ovarian cancer.
2023. Clin Cancer Res. Urinary tumor DNA MRD analysis to identify responders to neoadjuvant immunotherapy in muscle-invasive bladder cancer.
2023. J Med Chem. Selective covalent targeting of pyruvate kinase M2 using arsenous warheads.
2022. Oncogene. SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer.
2022. Cancer Res. Dual inhibition of CDK12/CDK13 targets both tumor and immune cells in ovarian cancer.
2020. Nat Commun. Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy.
2019. Elife. PAX8 regulon in human ovarian cancer links lineage dependency with epigenetic vulnerability to HDAC inhibitors.
2018. Nat Commun. Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors.
2018. Oncogene. Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics.
2018. Clin Cancer Res. Molecular targeted therapies elicit concurrent apoptotic and GSDME-dependent pyroptotic tumor cell death.
2017. Nat Commun. Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer.
2017. Cancer Res. Clonality, heterogeneity, and evolution of synchronous bilateral ovarian cancer.
